Andrei M Mikheev1, Svetlana A Mikheeva1, Andrew D Trister1, Mari J Tokita1, Samuel N Emerson1, Carolina A Parada1, Donald E Born1, Barbara Carnemolla1, Sam Frankel1, Deok-Ho Kim1, Rob G Oxford1, Yoshito Kosai1, Kathleen R Tozer-Fink1, Thomas C Manning1, John R Silber1, Robert C Rostomily1. 1. Department of Neurological Surgery, University of Washington School of Medicine, Seattle, Washington (A.M.M., S.A.M, S.N.E., C.A.P., R.G.O., J.R.S., R.C.R.); Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington (A.D.T.); Division of Medical Genetics, Department of Internal Medicine, University of Washington School of Medicine, Seattle, Washington (M.J.T); Department of Bioengineering, University of Washington School of Medicine, Seattle, Washington (S.F., D.-H.K.); Department of Radiology, University of Washington School of Medicine, Seattle, Washington (K.R.T.-F.); Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, Seattle, Washington (A.M.M., S.A.M., S.F., D.-H.K., R.C.R.); Sage Bionetworks, Seattle, Washington (A.D.T.); Neuropathology Service, Department of Pathology, Stanford University School of Medicine, Stanford, California (D.E.B.); Laboratory of Immunology, IRCCS San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (B.C.); Case Western Reserve School of Medicine, Cleveland, Ohio (Y.K.); Neuroscience Associates, Boise, Idaho (T.C.M.).
Abstract
BACKGROUND: Periostin is a secreted matricellular protein critical for epithelial-mesenchymal transition and carcinoma metastasis. In glioblastoma, it is highly upregulated compared with normal brain, and existing reports indicate potential prognostic and functional importance in glioma. However, the clinical implications of periostin expression and function related to its therapeutic potential have not been fully explored. METHODS: Periostin expression levels and patterns were examined in human glioma cells and tissues by quantitative real-time PCR and immunohistochemistry and correlated with glioma grade, type, recurrence, and survival. Functional assays determined the impact of altering periostin expression and function on cell invasion, migration, adhesion, and glioma stem cell activity and tumorigenicity. The prognostic and functional relevance of periostin and its associated genes were analyzed using the TCGA and REMBRANDT databases and paired recurrent glioma samples. RESULTS: Periostin expression levels correlated directly with tumor grade and recurrence, and inversely with survival, in all grades of adult human glioma. Stromal deposition of periostin was detected only in grade IV gliomas. Secreted periostin promoted glioma cell invasion and adhesion, and periostin knockdown markedly impaired survival of xenografted glioma stem cells. Interactions with αvβ3 and αvβ5 integrins promoted adhesion and migration, and periostin abrogated cytotoxicity of the αvβ3/β5 specific inhibitor cilengitide. Periostin-associated gene signatures, predominated by matrix and secreted proteins, corresponded to patient prognosis and functional motifs related to increased malignancy. CONCLUSION: Periostin is a robust marker of glioma malignancy and potential tumor recurrence. Abrogation of glioma stem cell tumorigenicity after periostin inhibition provides support for exploring the therapeutic impact of targeting periostin.
BACKGROUND:Periostin is a secreted matricellular protein critical for epithelial-mesenchymal transition and carcinoma metastasis. In glioblastoma, it is highly upregulated compared with normal brain, and existing reports indicate potential prognostic and functional importance in glioma. However, the clinical implications of periostin expression and function related to its therapeutic potential have not been fully explored. METHODS:Periostin expression levels and patterns were examined in humanglioma cells and tissues by quantitative real-time PCR and immunohistochemistry and correlated with glioma grade, type, recurrence, and survival. Functional assays determined the impact of altering periostin expression and function on cell invasion, migration, adhesion, and glioma stem cell activity and tumorigenicity. The prognostic and functional relevance of periostin and its associated genes were analyzed using the TCGA and REMBRANDT databases and paired recurrent glioma samples. RESULTS:Periostin expression levels correlated directly with tumor grade and recurrence, and inversely with survival, in all grades of adult humanglioma. Stromal deposition of periostin was detected only in grade IV gliomas. Secreted periostin promoted glioma cell invasion and adhesion, and periostin knockdown markedly impaired survival of xenografted glioma stem cells. Interactions with αvβ3 and αvβ5 integrins promoted adhesion and migration, and periostin abrogated cytotoxicity of the αvβ3/β5 specific inhibitor cilengitide. Periostin-associated gene signatures, predominated by matrix and secreted proteins, corresponded to patient prognosis and functional motifs related to increased malignancy. CONCLUSION:Periostin is a robust marker of glioma malignancy and potential tumor recurrence. Abrogation of glioma stem cell tumorigenicity after periostin inhibition provides support for exploring the therapeutic impact of targeting periostin.
Authors: A Lal; A E Lash; S F Altschul; V Velculescu; L Zhang; R E McLendon; M A Marra; C Prange; P J Morin; K Polyak; N Papadopoulos; B Vogelstein; K W Kinzler; R L Strausberg; G J Riggins Journal: Cancer Res Date: 1999-11-01 Impact factor: 12.701
Authors: K Horiuchi; N Amizuka; S Takeshita; H Takamatsu; M Katsuura; H Ozawa; Y Toyama; L F Bonewald; A Kudo Journal: J Bone Miner Res Date: 1999-07 Impact factor: 6.741
Authors: Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin Journal: Cancer Res Date: 2009-04-07 Impact factor: 12.701
Authors: Shideng Bao; Gaoliang Ouyang; Xuefang Bai; Zhi Huang; Chaoyu Ma; Ming Liu; Rong Shao; Ryan M Anderson; Jeremy N Rich; Xiao-Fan Wang Journal: Cancer Cell Date: 2004-04 Impact factor: 31.743
Authors: Pascal O Zinn; Bhanu Mahajan; Bhanu Majadan; Pratheesh Sathyan; Sanjay K Singh; Sadhan Majumder; Ferenc A Jolesz; Rivka R Colen Journal: PLoS One Date: 2011-10-05 Impact factor: 3.240
Authors: Kenji Izuhara; Simon J Conway; Bethany B Moore; Hisako Matsumoto; Cecile T J Holweg; John G Matthews; Joseph R Arron Journal: Am J Respir Crit Care Med Date: 2016-05-01 Impact factor: 21.405
Authors: Pascal O Zinn; Sanjay K Singh; Aikaterini Kotrotsou; Islam Hassan; Ginu Thomas; Markus M Luedi; Ahmed Elakkad; Nabil Elshafeey; Tagwa Idris; Jennifer Mosley; Joy Gumin; Gregory N Fuller; John F de Groot; Veera Baladandayuthapani; Erik P Sulman; Ashok J Kumar; Raymond Sawaya; Frederick F Lang; David Piwnica-Worms; Rivka R Colen Journal: Clin Cancer Res Date: 2018-07-27 Impact factor: 12.531
Authors: Kui Wang; Forrest M Kievit; Ariane E Erickson; John R Silber; Richard G Ellenbogen; Miqin Zhang Journal: Adv Healthc Mater Date: 2016-11-02 Impact factor: 9.933
Authors: Eric N Horst; Michael E Bregenzer; Pooja Mehta; Catherine S Snyder; Taylor Repetto; Yang Yang-Hartwich; Geeta Mehta Journal: Acta Biomater Date: 2021-04-30 Impact factor: 10.633
Authors: Lauren N Alfino; Kai C Wilczewski-Shirai; Kathryn E Cronise; Jonathan Coy; Kristina Glapa; E J Ehrhart; Joseph B Charles; Dawn L Duval; Daniel P Regan Journal: Vet Pathol Date: 2021-03-09 Impact factor: 3.157
Authors: Manny D Bacolod; Swadesh K Das; Upneet K Sokhi; Steven Bradley; David A Fenstermacher; Maurizio Pellecchia; Luni Emdad; Devanand Sarkar; Paul B Fisher Journal: Adv Cancer Res Date: 2015-05-23 Impact factor: 6.242